A groundbreaking artificial intelligence-powered genomics platform that dramatically accelerates whole genome sequencing is set to be unveiled at a major medical conference in Silicon Valley.
BioAro, a global leader in precision health, will introduce its AI-driven PanOmiQ platform at the Precision Medicine World Conference (PMWC). The new system can complete genome analysis in under two hours and generate Variant Call Format (VCF) files in less than five minutes—a significant advancement in medical science.
The company says this innovation will transform precision medicine by making genetic analysis faster, more accurate, and widely accessible.
“PanOmiQ isn’t just a technological advancement—it’s a game-changer for global healthcare,” said BioAro’s Chairman and CEO, Dr Anmol S. Kapoor. “By cutting genome analysis time from days to hours, we’re ensuring precision medicine is available to everyone, not just the privileged few.”
The use of AI in genomics has long been seen as a way to speed up and reduce the costs of sequencing. Traditional methods have often been time-consuming and expensive, limiting their accessibility. BioAro says PanOmiQ removes these barriers, allowing hospitals, researchers, and healthcare providers to deliver faster, data-driven treatments.
The platform’s speed and efficiency are expected to benefit multiple areas of medicine, including cancer research, rare disease diagnostics, and infectious disease monitoring.
Dr Raja B. Singh, BioAro’s Chief Scientific Officer, will present the PanOmiQ platform at PMWC, showcasing how AI-driven genomic analysis can help expand access to advanced healthcare.
“The future of precision medicine lies in real-time genetic insights,” Dr Singh said. “AI-driven accuracy at this scale ensures better diagnostics, targeted treatments, and groundbreaking discoveries in areas like cancer and rare genetic diseases.”
One of PanOmiQ’s most significant achievements is its variant calling proficiency. In August 2024, the platform achieved a 100% match in variant calling during testing by the College of American Pathologists (CAP), making it one of the most accurate genomic tools available.
Such precision ensures that healthcare professionals can trust the insights provided by genomic data, improving patient care and advancing research.
The unveiling of PanOmiQ comes at a time when AI is playing an increasingly prominent role in medicine. As healthcare systems worldwide seek ways to optimise resources and improve patient outcomes, AI-driven solutions like PanOmiQ offer a way to make genomic medicine more efficient and affordable.
By integrating AI into genomic analysis, BioAro aims to shift medicine from a reactive model—treating illnesses after symptoms appear—to a preventative approach that identifies risks early. The company says this shift will help reduce healthcare costs while improving patient longevity.
With applications in cancer treatment, rare disease diagnosis, and infectious disease tracking, PanOmiQ is expected to have a lasting impact on global healthcare.
The official unveiling at PMWC Silicon Valley marks a milestone in medical innovation, demonstrating how AI and genomics can work together to improve access to personalised medicine on a global scale.